B. Riley Comments on InfuSystem’s Q2 Earnings (NYSE:INFU)

InfuSystem Holdings, Inc. (NYSE:INFU) – Research analysts at B. Riley cut their Q2 2025 earnings per share (EPS) estimates for InfuSystem in a research note issued on Tuesday, March 4th. B. Riley analyst K. Bauser now expects that the company will post earnings of $0.05 per share for the quarter, down from their previous forecast of $0.06. The consensus estimate for InfuSystem’s current full-year earnings is $0.15 per share. B. Riley also issued estimates for InfuSystem’s FY2025 earnings at $0.23 EPS.

Separately, StockNews.com downgraded InfuSystem from a “strong-buy” rating to a “buy” rating in a research note on Thursday.

InfuSystem Trading Down 2.2 %

INFU opened at $6.11 on Thursday. The firm has a market cap of $129.92 million, a price-to-earnings ratio of 101.85 and a beta of 1.75. InfuSystem has a 52 week low of $5.74 and a 52 week high of $9.97. The business’s 50 day moving average is $7.96 and its two-hundred day moving average is $7.60. The company has a quick ratio of 1.59, a current ratio of 1.98 and a debt-to-equity ratio of 0.50.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of INFU. BNP Paribas Financial Markets grew its stake in shares of InfuSystem by 66.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 4,076 shares of the company’s stock valued at $27,000 after purchasing an additional 1,626 shares during the last quarter. Wells Fargo & Company MN grew its stake in shares of InfuSystem by 51.7% in the 4th quarter. Wells Fargo & Company MN now owns 9,286 shares of the company’s stock valued at $78,000 after purchasing an additional 3,165 shares during the last quarter. Legato Capital Management LLC purchased a new stake in shares of InfuSystem in the fourth quarter valued at approximately $85,000. Summit Global Investments purchased a new stake in shares of InfuSystem in the fourth quarter valued at approximately $86,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of InfuSystem in the third quarter valued at approximately $87,000. 71.13% of the stock is currently owned by hedge funds and other institutional investors.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.